BioStock Studio: Cyxone on the phase IIb study

In September, biotech company Cyxone was approved by Polish authorities to start a phase IIb trial with drug candidate Rabeximod in rheumatoid arthritis. The ambition is to develop a safe treatment with a new mechanism of action in an area of significant medical need. This is a milestone for Cyxone which also will conduct the study in additional countries. Carl-Magnus Högerkorp, acting CEO, visited BioStock's studio and talked about the approval and the trial.

Watch the interview with Cyxone's acting CEO Carl-Magnus Högerkorp at biostock.se:

https://www.biostock.se/en/2022/10/cyxone-on-the-phase-iib-study/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/